# A Study of Amivantamab Monotherapy in Participants With Previously Treated Advanced Hepatocellular Carcinoma

> **NCT05653427** · PHASE2 · TERMINATED · sponsor: **Janssen Research & Development, LLC** · enrollment: 18 (actual)

## Conditions studied

- Carcinoma, Hepatocellular

## Interventions

- **DRUG:** Amivantamab

## Key facts

- **NCT ID:** NCT05653427
- **Lead sponsor:** Janssen Research & Development, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-12-08
- **Primary completion:** 2023-10-10
- **Final completion:** 2023-10-10
- **Target enrollment:** 18 (ACTUAL)
- **Why stopped:** N\~15 subjects data analysis did not meet statistical consideration of ORR and study primary/secondary objectives were not met. Enrollment was terminated for futility
- **Last updated:** 2025-01-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05653427

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05653427, "A Study of Amivantamab Monotherapy in Participants With Previously Treated Advanced Hepatocellular Carcinoma". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT05653427. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*